The trial of a $200 million gender discrimination class action suit against Swiss-owned drug maker Novartis Pharmaceuticals began Thursday with the defense saying the company “makes no claim that we are perfect” but denying that it underpaid women or intentionally promoted them less frequently than men.
“This isn’t a company with a glass ceiling,” defense attorney Richard Schnadig told the jury of six women and four men in the closely watched case.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]